

Supplementary Table 1

Response, n (%)	irRECIST, central imaging review (N=51)	mRECIST, central imaging review (N=51)	RECIST 1.1, investigator's review (N=51)
ORR, % (95% CI)	18 (8-31)	18 (8-31)	18 (8-31)
DCR, % (95% CI)	61 (46-74)	51 (37-65)	59 (44-72)
Best overall response, n (%)			
Complete response	1 (2)	3 (6)	1 (2)
Partial response	8 (16)	6 (12)	8 (16)
Stable disease	22 (43)	17 (33)	21 (41)
Progressive disease	15 (29)	17 (33)	17 (33)
Non-evaluable*	2 (4)	2 (4)	1 (2)
No evidence of disease†	0	2 (4)	0
No assessment‡	3 (6)	3 (6)	3 (6)
Time to response, median (range), months	6 (2-13)	2 (2-10)	4 (2-4)
DOR, median (range), months	16 (3-24+)	16 (3-23+)	20 (3-21)